Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001641172-25-010298
Filing Date
2025-05-14
Accepted
2025-05-14 16:30:21
Documents
44
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q form10-q.htm   iXBRL 10-Q 550963
2 EX-31.1 ex31-1.htm EX-31.1 17429
3 EX-31.2 ex31-2.htm EX-31.2 13792
4 EX-32.1 ex32-1.htm EX-32.1 8381
  Complete submission text file 0001641172-25-010298.txt   2835415

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE telo-20250331.xsd EX-101.SCH 20600
6 XBRL CALCULATION FILE telo-20250331_cal.xml EX-101.CAL 24363
7 XBRL DEFINITION FILE telo-20250331_def.xml EX-101.DEF 66904
8 XBRL LABEL FILE telo-20250331_lab.xml EX-101.LAB 189439
9 XBRL PRESENTATION FILE telo-20250331_pre.xml EX-101.PRE 144385
46 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 373351
Mailing Address 100 SE 2ND ST SUITE 2000 #1009 MIAMI FL 33131
Business Address 100 SE 2ND ST SUITE 2000 #1009 MIAMI FL 33131 786-396-6723
Telomir Pharmaceuticals, Inc. (Filer) CIK: 0001971532 (see all company filings)

EIN.: 872606031 | State of Incorp.: FL | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41952 | Film No.: 25946236
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)